BeiGene (BGNE) Competitors $176.50 +1.78 (+1.02%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BGNE vs. TAK, BNTX, TEVA, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, and CTLTShould you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. BeiGene vs. Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Takeda Pharmaceutical (NYSE:TAK) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking. Does the media favor TAK or BGNE? In the previous week, BeiGene had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for BeiGene and 2 mentions for Takeda Pharmaceutical. BeiGene's average media sentiment score of 0.97 beat Takeda Pharmaceutical's score of 0.61 indicating that BeiGene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeiGene 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in TAK or BGNE? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 48.5% of BeiGene shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 7.4% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer TAK or BGNE? BeiGene has a consensus price target of $253.69, indicating a potential upside of 43.73%. Given BeiGene's stronger consensus rating and higher probable upside, analysts plainly believe BeiGene is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BeiGene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is TAK or BGNE more profitable? Takeda Pharmaceutical has a net margin of 6.49% compared to BeiGene's net margin of -25.94%. Takeda Pharmaceutical's return on equity of 10.00% beat BeiGene's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% BeiGene -25.94%-25.12%-14.95% Which has more risk & volatility, TAK or BGNE? Takeda Pharmaceutical has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Which has higher valuation & earnings, TAK or BGNE? Takeda Pharmaceutical has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5822.59BeiGene$3.32B5.19-$881.71M-$8.24-21.42 Does the MarketBeat Community favor TAK or BGNE? BeiGene received 447 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 69.24% of users gave BeiGene an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% BeiGeneOutperform Votes54769.24% Underperform Votes24330.76% SummaryBeiGene beats Takeda Pharmaceutical on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGNE vs. The Competition Export to ExcelMetricBeiGenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.20B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-21.4210.5991.3417.19Price / Sales5.19195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book4.765.104.794.78Net Income-$881.71M$151.51M$120.07M$225.60M7 Day Performance-1.59%-2.14%-1.90%-1.24%1 Month Performance-9.28%-3.13%11.43%3.06%1 Year Performance-0.33%11.51%30.59%16.50% BeiGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGNEBeiGene2.6115 of 5 stars$176.50+1.0%$253.69+43.7%+0.7%$17.20B$3.32B-21.4210,600TAKTakeda Pharmaceutical4.3944 of 5 stars$13.34-0.6%N/A-4.3%$42.45B$28.20B23.1449,281BNTXBioNTech2.084 of 5 stars$114.07-5.2%$140.76+23.4%+10.0%$27.12B$3.04B-56.016,133TEVATeva Pharmaceutical Industries1.8805 of 5 stars$16.66+1.0%$19.67+18.0%+112.2%$18.87B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageMRNAModerna4.2664 of 5 stars$41.59-0.6%$79.50+91.2%-54.3%$16.00B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0581 of 5 stars$12.71+0.6%$13.67+7.5%+19.8%$15.17B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2652 of 5 stars$18.71+4.9%$33.33+78.2%+636.9%$13.80B$700,000.00-63.68105News CoverageGMABGenmab A/S4.2355 of 5 stars$20.14-0.1%$45.20+124.4%-33.5%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8457 of 5 stars$14.75+2.0%$17.00+15.3%+15.8%$12.31B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$126.12+1.9%$178.71+41.7%+31.8%$12.05B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7788 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading Volume Related Companies and Tools Related Companies TAK Competitors BNTX Competitors TEVA Competitors MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors SRPT Competitors CTLT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BGNE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeiGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BGNE Stock Alerts